Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR increased in 2014: 3.268
Rank 106 out of 289 in category Biochemistry & Molecular Biology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 1.596
Source Normalized Impact per Paper (SNIP) 2014: 0.845
Impact per Publication (IPP) 2014: 2.992

VolumeIssuePage

Issues

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

Nigel Irwin1 / Victor A. Gault2 / Brian D. Green3 / Brett Greer4 / Jane T. McCluskey5 / Patrick Harriott6 / Finbarr P.M. O’Harte7 / Peter R. Flatt8

1.

2.

3.

4.

5.

6.

7.

8.

Citation Information: Biological Chemistry. Volume 385, Issue 9, Pages 845–852, ISSN (Print) 1431-6730, DOI: 10.1515/BC.2004.110, June 2005

Publication History

Received:
June 30, 2004
Accepted:
August 4, 2004
Published Online:
2005-06-01

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by endocrine K-cells in response to nutrient absorption. In this study we have utilized a specific and enzymatically stable GIP receptor antagonist, (Pro3)GIP, to evaluate the contribution of endogenous GIP to insulin secretion and glucose homeostasis in mice. Daily injection of (Pro3)GIP (25 nmol/kg body weight) for 11 days had no effect on food intake or body weight. Non-fasting plasma glucose concentrations were significantly raised (p<0.05) by day 11, while plasma insulin concentrations were not significantly different from saline treated controls. After 11 days, intraperitoneal glucose tolerance was significantly impaired in the (Pro3)GIP treated mice compared to control (p<0.01). Glucose-mediated insulin secretion was not significantly different between the two groups. Insulin sensitivity of 11-day (Pro3)GIP treated mice was slightly impaired 60 min post injection compared with controls. Following a 15 min refeeding period in 18 h fasted mice, food intake was not significantly different in (Pro3)GIP treated mice and controls. However, (Pro3)GIP treated mice displayed significantly elevated plasma glucose levels 30 and 60 min post feeding (p<0.05, in both cases). Postprandial insulin secretion was not significantly different and no changes in pancreatic insulin content or islet morphology were observed in (Pro3)GIP treated mice. The observed biological effects of (Pro3)GIP were reversed following cessation of treatment for 9 days. These data indicate that ablation of GIP signaling causes a readily reversible glucose intolerance without appreciable change of insulin secretion.

Keywords: enteroinsular axis; GIP receptor antagonist; (Pro3)GIP

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Daniel J. Drucker
Cell Metabolism, 2006, Volume 3, Number 3, Page 153
[2]
Surendra Ugale, Neeraj Gupta, Kirtikumar D Modi, Sunil K Kota, Vasisht Satwalekar, Vishwas Naik, Modukuri Swapna, and KVS Kumar
Journal of Diabetes & Metabolic Disorders, 2014, Volume 13, Number 1, Page 89
[3]
Hale M. Tasyurek, Hasan Ali Altunbas, Mustafa Kemal Balci, and Salih Sanlioglu
Diabetes/Metabolism Research and Reviews, 2014, Volume 30, Number 5, Page 354
[4]
Ana I Calleja, Elisa Cortijo, Pablo García-Bermejo, Javier Reyes RN, Jesús F Bermejo, M. Fe Muñoz BS, Rosario Fernández-Herranz, and Juan F Arenillas
Journal of Diabetes Research and Clinical Metabolism, 2013, Volume 2, Number 1, Page 2
[5]
Karl J Neff and Carel W le Roux
Clinical Lipidology, 2013, Volume 8, Number 1, Page 109
[6]
Sunil Kumar Kota, Surendra Ugale, Neeraj Gupta, and Kirtikumar D. Modi
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2012, Volume 6, Number 3, Page 125
[7]
Liza K. Phillips and Johannes B. Prins
Annals of the New York Academy of Sciences, 2011, Volume 1243, Number 1, Page E55
[8]
Laurie L. Baggio and Daniel J. Drucker
Gastroenterology, 2007, Volume 132, Number 6, Page 2131
[11]
Augusto Tinoco, Luciana El-Kadre, Livia Aquiar, Renam Tinoco, and Paulo Savassi-Rocha
World Journal of Surgery, 2011, Volume 35, Number 10, Page 2238
[12]
Nigel Irwin, Brian D. Green, Victor A. Gault, Roslyn S. Cassidy, Finbarr P.M. O’Harte, Patrick Harriott, and Peter R. Flatt
Peptides, 2006, Volume 27, Number 4, Page 893
[13]
Nigel Irwin and Peter R. Flatt
Best Practice & Research Clinical Endocrinology & Metabolism, 2009, Volume 23, Number 4, Page 499
[14]
Victor A. Gault, Kerry Hunter, Nigel Irwin, Brett Greer, Brian D. Green, Patrick Harriott, Finbarr P.M. O'Harte, and Peter R. Flatt
Biological Chemistry, 2007, Volume 388, Number 2
[15]
Ju-Hee Kim, Sung-Dae Moon, Seung-Hyun Ko, Yu-Bai Ahn, Ki-Ho Song, Hyang-Sook Lim, Sook-Kyung Lee, Soon-Jip Yoo, Hyun-Shik Son, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Sung-Joo Yoon Kim, and Je-Ho Han
The Journal of Korean Diabetes Association, 2007, Volume 31, Number 1, Page 9
[17]
Aureo Ludovico DePaula, A. L. V. Macedo, V. Schraibman, B. R. Mota, and S. Vencio
Surgical Endoscopy, 2009, Volume 23, Number 8, Page 1724

Comments (0)

Please log in or register to comment.